You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Tazemetostat (EPZ-6438)

Showing 1 - 25 of 48
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent DLBCL Germinal Center B-Cell Type, Recurrent Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma Trial (Belinostat,

Not yet recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
  • +5 more
  • (no location specified)
Dec 2, 2022

Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma Trial in Duarte (Tazemetostat, Ublituximab, Umbralisib)

Not yet recruiting
  • Recurrent Follicular Lymphoma
  • Refractory Follicular Lymphoma
  • Duarte, California
    City of Hope Medical Center
Jul 31, 2022

All Malignancies, Advanced Malignancies, Hematologic Malignancy Trial in Spain, United States (Tazemetostat, Itraconazole,

Active, not recruiting
  • All Malignancies
  • +11 more
  • Encinitas, California
  • +9 more
May 20, 2022

Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer Trial in Boston (Talazoparib, Tazemetostat)

Recruiting
  • Metastatic Prostate Cancer
  • Metastatic Castration-resistant Prostate Cancer
  • Boston, Massachusetts
  • +1 more
Jul 18, 2022

Epithelioid Sarcoma (Ex-US Only), Spindle Cell Sarcoma, Sinonasal Carcinoma Trial (Tazemetostat)

Temporarily not available
  • Epithelioid Sarcoma (Ex-US Only)
  • +19 more
  • (no location specified)
Oct 17, 2022

Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Philadelphia (Palbociclib, Tazemetostat,

Not yet recruiting
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Philadelphia, Pennsylvania
    Thomas Jefferson University Hospital
Jan 13, 2023

Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma Trial in United States (Dabrafenib Mesylate, Tazemetostat

Recruiting
  • Clinical Stage IV Cutaneous Melanoma AJCC v8
  • Metastatic Melanoma
  • Dabrafenib Mesylate
  • +2 more
  • Atlanta, Georgia
  • +6 more
Nov 30, 2022

Diffuse Large B Cell Lymphoma, Primary Mediastinal Lymphoma, Mantle Cell Lymphoma Trial in Tucson, Tampa, New York

Completed
Has Results
  • Diffuse Large B Cell Lymphoma
  • +4 more
  • Tucson, Arizona
  • +2 more
Mar 23, 2021

Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Platinum-Resistant Lung Small Cell Carcinoma

Recruiting
  • Extensive Stage Lung Small Cell Carcinoma
  • +3 more
  • Biopsy
  • +4 more
  • Los Angeles, California
  • +8 more
Jan 31, 2023

Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6

Not yet recruiting
  • Grade 3b Follicular Lymphoma
  • +5 more
  • Biospecimen Collection
  • +9 more
  • (no location specified)
Jun 6, 2023

Lymphoma, DLBCL, Follicular Lymphoma Trial in Belgium, France (Tazemetostat, Rituximab, Cyclophosphamide)

Recruiting
  • Lymphoma
  • +2 more
  • Bruxelles, Belgium
  • +30 more
Jul 23, 2021

Malignant Rhabdoid Tumors (MRT), Rhabdoid Tumors of the Kidney (RTK), Atypical Teratoid Rhabdoid Tumors (ATRT) Trial in

Active, not recruiting
  • Malignant Rhabdoid Tumors (MRT)
  • +10 more
  • San Francisco, California
  • +31 more
Jan 17, 2023

B-cell Lymphomas (Phase 1), Advanced Solid Tumors (Phase 1), Diffuse Large B-cell Lymphoma (Phase 2) Trial in Worldwide

Completed
  • B-cell Lymphomas (Phase 1)
  • +5 more
  • Birmingham, Alabama
  • +51 more
Dec 8, 2021

Follicular Lymphoma Trial in United States (Tazemetostat, Rituximab)

Recruiting
  • Follicular Lymphoma
  • Birmingham, Alabama
  • +19 more
Mar 29, 2022

Follicular Lymphoma, Non Hodgkin Lymphoma, Lymphoma Trial in Edmonds, Issaquah, Seattle (Tazemetostat, Rituximab)

Terminated
  • Follicular Lymphoma
  • +2 more
  • Edmonds, Washington
  • +2 more
Mar 1, 2021

Advanced Soft Tissue Sarcoma, Advanced Epithelioid Sarcoma Trial in Worldwide (Tazemetostat, Placebo, Doxorubicin HCl)

Recruiting
  • Advanced Soft Tissue Sarcoma
  • Advanced Epithelioid Sarcoma
  • Duarte, California
  • +20 more
Jan 31, 2022

Diffuse Large B Cell Lymphoma, Primary Mediastinal Lymphoma, Mantle-Cell Lymphoma Trial in Bebington, Liverpool (Tazemetostat

Completed
  • Diffuse Large B Cell Lymphoma
  • +5 more
  • Tazemetostat and [14C] Tazemetostat
  • Bebington, Wirral, United Kingdom
  • +1 more
Jan 8, 2020

Mesothelioma, BAP1 Loss of Function Trial in France, United Kingdom, United States (Tazemetostat)

Completed
Has Results
  • Mesothelioma
  • BAP1 Loss of Function
  • Los Angeles, California
  • +15 more
Mar 16, 2021

Rhabdoid Tumors, INI1-negative Tumors, Synovial Sarcoma Trial in Worldwide (Tazemetostat)

Completed
  • Rhabdoid Tumors
  • +3 more
  • Los Angeles, California
  • +34 more
Dec 23, 2021

Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma, Metastatic Malignant Solid

Withdrawn
  • Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma
  • +10 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Baltimore, Maryland
    Johns Hopkins University/Sidney Kimmel Cancer Center
Feb 6, 2020

Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma

Active, not recruiting
  • Recurrent Endometrial Endometrioid Adenocarcinoma
  • +4 more
  • Anchorage, Alaska
  • +584 more
Jan 28, 2023

Lymphoma Trial in Worldwide (Atezolizumab, Obinutuzumab, Tazemetostat)

Completed
  • Lymphoma
  • Duarte, California
  • +14 more
Jan 22, 2020

Relapsed/Refractory Lymphoma Trial in Shanghai (tazemetostat, HMPL-689)

Not yet recruiting
  • Relapsed/Refractory Lymphoma
  • Shanghai, China
    Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Feb 2, 2023

Relapsed/Refractory Follicular Lymphoma With EZH2 Trial in Shanghai (Tazemetostat)

Not yet recruiting
  • Relapsed/Refractory Follicular Lymphoma With EZH2
  • Shanghai, Shanghai, China
    Shanghai Cancer Center
Jul 20, 2022

Solid Tumor, ARID1A Gene Mutation Trial in Greenville (Tazemetostat)

Suspended
  • Solid Tumor
  • ARID1A Gene Mutation
  • Greenville, South Carolina
    Prisma Health Cancer Institute
Jan 10, 2023